Not medical advice. MOTS-C is a research compound. This guide does not provide dosing, diagnosis, therapy recommendations, or claims about effects in humans.
MOTS-C is listed in our catalogue under “Metabolic / Longevity.” In scientific publications it is discussed in technical language; this page translates the general themes into everyday wording while staying faithful to research-only framing.
One-paragraph overview from our research datasheet — still scientific, but faster to read than the full mechanism list below.
MOTS-c mitochondrial-derived peptide activates AMPK via folate-AICAR pathway to regulate glucose metabolism, insulin sensitivity, and lipid oxidation.
Peer-reviewed literature typically discusses MOTS-C in specific experimental settings. The points below reflect how the scientific community frames this compound—not as health claims, but as the research questions being asked.
Research vs. personal use: Literature describes experiments in controlled lab and animal models. This is distinct from any real-world use; our products are for laboratory research only.
Researchers study these compounds for mitochondrial function, nutrient sensing, and cellular energy stress responses -often in ageing or metabolic disease models.
Our datasheet lists mechanistic themes observed in preclinical work. These are research endpoints, not health claims. They help scientists understand and compare pathways.
Storage requirements: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation. · Learn best practices in our detailed storage guide.
Research dosing context: Literature typically discusses 5–10 mg subcutaneous injection · 3 times weekly (e.g., Mon/Wed/Fri) for 4–6 weeks, then 1x/week maintenance · Estimated circulating half-life of 1–2 hours based on post-exercise endogenous kinetics. Morning administration 30–60 minutes before fasted exercise is preferred to align with physiological production patterns. No formal human pharmacokinetic studies published; dosing derived from preclinical protocols (15 mg/kg 3x/week in aged mice, Lee et al., 2015).
Preparation steps: Follow our detailed reconstitution guide, use the calculator tool for volume confirmation, and always verify purity with the COA reading guide.
MOTS-c (Mitochondrial Open-reading-frame of the Twelve S rRNA type-c) is a 16-amino-acid mitochondrial-derived peptide encoded within mitochondrial DNA. It acts as a metabolic signalling peptide, notably activating the AMPK energy-sensing pathway. It is supplied as a lyophilised research-grade powder for laboratory use only.
In research models MOTS-c activates AMPK and influences metabolic homeostasis — glucose handling, insulin sensitivity and mitochondrial energy metabolism — which is why it is studied as a candidate "exercise-mimetic" signalling peptide. These are findings in cell and animal models; New-U supplies it for laboratory research only and implies no human effect.
In the research literature MOTS-c is used as a tool compound to study mitochondrial signalling, AMPK activation, metabolic and exercise-physiology endpoints, and age-related metabolic decline. New-U supplies it strictly for in-vitro and animal-model research; it is not for human use.
A mitochondrial-derived peptide (MDP) is a short bioactive peptide encoded directly by mitochondrial DNA - specifically by small open reading frames hidden inside genes for mitochondrial ribosomal RNAs. MOTS-c (from 12S rRNA) and humanin (from 16S rRNA) are the two best-studied examples. Their discovery made mitochondria into a genuine endocrine organ that signals to the rest of the body.
In preclinical models, yes. MOTS-c reproduces several characteristic metabolic effects of exercise - AMPK activation, improved insulin sensitivity, increased mitochondrial biogenesis, restored running capacity in aged animals - without the animal actually exercising. Whether those effects translate to humans in comparable ways is still an open research question.
Morning administration, 30-60 minutes before fasted exercise, is the pattern most commonly used. The timing aligns exogenous MOTS-c with the window where endogenous production naturally peaks during exercise, and fasted state maximises AMPK responsiveness.
Keep the lyophilised powder frozen at −20 °C. After reconstitution with bacteriostatic water, refrigerate at 1-6 °C and protect from light. MOTS-c is reasonably stable in solution within the normal peptide-handling window.
MOTS-c is a mitochondrial-derived peptide studied as a metabolic/AMPK-signalling molecule rather than a hormone. In the research models, its short residence time means that once administration stops the peptide clears and the metabolic signalling it stimulated returns toward baseline; the literature does not describe a hormonal suppression or withdrawal effect. These are preclinical research observations — MOTS-c is supplied for laboratory research only and is not for human use.
No, and no. This article is educational only. We do not provide dosing, medical recommendations, or health claims. Our products are sold strictly for laboratory research, not for personal use of any kind.
Open the shop listing via “View product details.” There you will see batch specs, the Certificate of Analysis (COA), concentration, purity grade, and available SKUs with current pricing.
Other compounds researchers often read about alongside MOTS-C.
Primary literature and registries for MOTS-C, plus mainstream coverage of the peptide category. Research use only - not medical advice.
Databases & literature:
Peptides in the news:
Access concentration, batch info, variants, and current pricing on our shop.
Also known as: MOTS-c, Mitochondrial ORF of 12S rRNA type-c, MOTS-C Peptide, Mitochondrial-Derived Peptide MOTS-c, MRWQEMGYIFYPRKLR, Exercise Mimetic Peptide, CB4211 Analog